Cohort profile: The centers for AIDS research network of integrated clinical systems

International Journal of Epidemiology

Volumn 37, Issue 5, 2008, Pages 948-955

  Kitahata, Mari M ^a   Rodriguez, Benigno ^b   Haubrich, Richard ^c   Boswell, Stephen ^d   Mathews, W Christopher ^c   Lederman, Michael M ^b   Lober, William B ^a   Van Rompaey, Stephen E ^a   Crane, Heidi M ^a   Moore, Richard D ^e   Bertram, Michael ^f   Kahn, James O ^g   Saag, Michael S ^f  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d HARVARD UNIVERSITY   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f University of Alabama at Birmingham   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COHORT ANALYSIS; RESEARCH;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; COHORT ANALYSIS; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT RESPONSE; TREND STUDY; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; COOPERATIVE BEHAVIOR; DELIVERY OF HEALTH CARE, INTEGRATED; FEMALE; HUMANS; MALE; MEDICAL RECORD LINKAGE; MIDDLE AGED; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 53349098905     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dym231     Document Type: Article

References (33)

1. Palellá FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among pailents with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 1998;338:853-60.
2. Whitman S, Murphy J, Cohen M, Sherer R. Marked declines in human immunodeficiency virus-related mortality in Chicago in women, African Americans, Hispanics, young adults, and injection drug users, from 1995 through 1997. Arch Intern Med 2000;160:365-69.
3. Hickman M, Bardsley M, De Angelis D, Ward H. Impact of HIV on adult (15-54) mortality in London: 1979-96. Sex Transm Infect 1999;75 385-88.
4. Murphy EL, Collier AC, Kalish LA et al. Highly active, antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135:17-26.
5. Deeks SG, Hecht FM, Swanson M et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy. AIDS 1999;13:F35-43.
6. May MT, Sterne JA, Costagliola D et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: A collaborative analysis. Lancet 2006;368:451-58.
7. Knobel H, Guelar A, Carmona A et al. Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors. AIDS Patient Care STDS 2001;15 193-99.
8. Yeni P, Cooper DA, Aboulker JP et al. Virological and immunological outcomes at 3 years after starting anti-retroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: Open-label randomised trial. Lancet 2006;368:287-98.
9. Dragsted UB, Mocroft A, Vella S et al. Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: A EuroSIDA study. J Infect Dis 2004; 190:148-55.
10. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med 1997;127:947.
11. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-58.
12. Behrens G, Dejam A, Schmidt H et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999;13:F63-70.
13. Walli R, Herfort O, Michl GM et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998;12 F167-73.
14. Mulligan K, Grunfeld C, Tai VW et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000;23:35-43.
15. Hughes MD. Initial treatment of HIV infection: Randomized trials with clinical end points are still needed. J Infect Dis 2006;194 542-44.
16. Lau B, Gange SJ, Moore RD. Interval and clinical cohort studies: epidemiological issues. AIDS Res Hum Retroviruses 2007;23 769-76.
17. Centers for Disease Control and Prevention. HIV/AIDS surveillance report. 2001;Vol. 13, No. 1, Available at: http://www.cdc.gov/hiv/ topics/surveillance/resources/reports/#surveillance.
18. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41 1-19.
19. CoDe Working Group. Protocol: Coding causes of death in HIV CoDe. v1.0: www.cphiv.dk/CoDe, last accessed date June 1, 2007.
20. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: The PHQ primary care study. Primary care evaluation of mental disorders. Patient health questionnaire. JAMA 1999;282:1737-44.
21. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med 2001;16:606-13.
22. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): An effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol use disorders identification test. Arch Intern Med 1998; 158:1789-95.
23. Bradley KA, Bush KR, Epler AJ et al. Two brief alcohol-screening tests from the Alcohol Use Disorders Identification Test (AUDIT): validation in a female veterans affairs patient population. Arch Intern Med 2003;163:821-29.
24. Newcombe DA, Humeniuk RE, Ali R. Validation of the World Health Organization Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): Report of results from the Australian site. Drug Alcohol Rev 2005;24:217-26.
25. WHO ASSIST Working Group. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): Development, reliability and feasibility. Addiction 2002;97:1183-94.
26. Gripshover B, Tien PC, Saag MS, Osmond D, Bacchetti P, Grunfeld C. Lipoatrophy is the dominant feature of the lipodystrophy syndrome in HIV-infected men. Paper presented at: 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2003.
27. Tien PC, Cole SR, Williams CM et al. Incidence of Lipoatrophy and Lipohypertrophy in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2003;34:461-66.
28. Bacchetti P, Gripshover B, Grunfeld C et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005;40 121-31.
29. Mathews WC, May S. EuroQol (EQ-5D) measure of quality of life predicts mortality, emergency department utilization, and hospital discharge rates in HIV-infected adults under care. Health Qual Life Outcomes 2007;5:5.
30. Kissinger P, Rice J, Farley T et al. Application of computer-assisted interviews to sexual behavior research. Am J Epidemiol 1999;149:950-54.
31. Rodriguez B, Sethi AK, Cheruvu VK et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 2006; 296:1498-506.
32. Gange SJ, Kitahata MM, Saag MS et al. Cohort Profile: The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol 2007;36:294-301.
33. ART-CC. ART cohort collaboration. http://www.art-cohort-collaboration.org, last accessed date June 1, 2007.